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Abstract
Purpose Nonalcoholic fatty liver disease (NAFLD) is defined by excessive lipid accumulation in the liver and involves an 
ample spectrum of liver diseases, ranging from simple uncomplicated steatosis to cirrhosis and hepatocellular carcinoma. 
Accumulating evidence demonstrates that high fructose intake enhances NAFLD development and progression promot-
ing inhibition of mitochondrial β-oxidation of long-chain fatty acids and oxidative damages. l-Carnitine (LC), involved in 
β-oxidation, has been used to reduce obesity caused by high-fat diet, which is beneficial to ameliorating fatty liver diseases. 
Moreover, in the recent years, various studies have established LC anti-oxidative proprieties. The objective of this study was 
to elucidate primarily the underlying anti-oxidative mechanisms of LC in an in vitro model of fructose-induced liver steatosis.
Methods Human hepatoma HepG2 cells were maintained in medium supplemented with LC (5 mM LC) with or without 
5 mM fructose (F) for 48 h and 72 h. In control cells, LC or F was not added to medium. Fat deposition, anti-oxidative, and 
mitochondrial homeostasis were investigated.
Results LC supplementation decreased the intracellular lipid deposition enhancing AMPK activation. However, compound 
C (AMPK inhibitor-10 μM), significantly abolished LC benefits in F condition. Moreover, LC, increasing PGC1 α expres-
sion, ameliorates mitochondrial damage-F induced. Above all, LC reduced ROS production and simultaneously increased 
protein content of antioxidant factors, SOD2 and Nrf2.
Conclusion Our data seemed to show that LC attenuate fructose-mediated lipid accumulation through AMPK activation. 
Moreover, LC counteracts mitochondrial damages and reactive oxygen species production restoring antioxidant cellular 
machine. These findings provide new insights into LC role as an AMPK activator and anti-oxidative molecule in NAFLD.
Keywords Hepatic steatosis · Metabolic disease · Fructose · l-Carnitine · Lipid deposition · Oxidative stress
Introduction
Nonalcoholic fatty liver disease (NAFLD), one of the most 
common cause of chronic liver diseases, is characterized 
by the abundant accumulation of triglycerides in hepato-
cytes, a condition that starts from a simple steatosis and 
may further progress to steatohepatitis (NASH), cirrho-
sis, and hepatocellular carcinoma [1, 2]. Since NAFLD 
patients are often overweight, over-nutrition achieves a 
fundamental role during the pathogenesis of hepatic lipid 
accumulation [3]. Several investigations have demon-
strated that a fructose (F) overconsumption is involved 
in NAFLD progression, stimulating de novo lipogenesis, 
production and secretion of triglyceride and very low-
density lipoprotein, and blocking fatty acid oxidation [4]. 
Moreover, recent data suggest how a chronically high fruc-
tose intake could inhibit AMP-activated protein kinase 
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(AMPK), the main energy sensor of cellular metabolism, 
whereas its activation counteracts NAFLD progression 
[5]. Additionally, literature documents have indicated that 
fructose-rich diet is associated with oxidative stress and, in 
particular, with the decrease of mitochondrial biogenesis 
and antioxidant machine [6]. In particular, high fructose 
intake leads to a dysregulation of nuclear factor E2-related 
factor 2 (Nrf2) expression that regulates mitochondrial 
antioxidant function enhancing synthesis of detoxifying 
enzymes [7]. Recently, Sharma et al. have revealed how in 
mice fed high fat plus fructose, Nrf2 pharmacological acti-
vation ameliorates insulin resistance and alleviates NASH 
and liver fibrosis, principally decreasing oxidative stress 
and inflammatory [8].
If an imbalance diet and altered cellular metabolism are 
the main causes of NAFLD progression, eating habit modi-
fications and, in general, weight reduction remain a first-
line strategy in NAFLD management [9]. The nutritional 
recommendations are even more important considering that 
a specific pharmacological intervention for NAFLD has not 
yet been identified. In effect, the various pharmacological 
treatments use specific drugs for coexisting diseases, namely 
the glucagon-like peptide 1 and the cotransport antagonist 
2 sodium/glucose (SGLT-2) for the control of glycaemia, in 
association with vitamin E supplementation [10]. Recently, 
novel therapeutic options for NAFLD have been proposed 
including activation of farnesoid X receptor (FXR) that ame-
liorates fibrotic and inflammatory damages [11, 12]. How-
ever, Mediterranean diet prefers low glycemic index prod-
ucts and antioxidant foods and, in general, weight reduction 
extremely effectively counteracts NAFLD progression [9].
In details, diet supplements or nutraceutical agents having 
cellular antioxidant activity are likely to have therapeutic 
capacities in NAFLD [9, 13]. For example, in rat fed with 
high fructose diet, curcumin relieves NAFLD activating 
Nrf2 signaling [14], while vitamin E significantly reduces 
the overproduction of ROS induced by fructose [6]. In par-
ticular, various clinical trials are underway to demonstrate 
the effectiveness of vitamin E in NAFLD management: 
Vilar-Gomez et al. have demonstrated that vitamin E sup-
plementation improved clinical outcomes in diabetic and no 
diabetic patients with NASH ameliorating fibrosis or cir-
rhosis [15]. Moreover, Sanyal et al. have compared vitamin 
E and pioglitazone efficacy in liver steatosis observing that 
vitamin E had a greater effectiveness for the treatment of 
nonalcoholic steatohepatitis in adults without diabetes [16].
l-Carnitine (LC) plays a critical role in a number of intra-
cellular and metabolic functions, such as fatty acid trans-
port into the mitochondria, stabilization of cell membranes, 
and reduction of serum lipid levels [17]. Moreover, recent 
evidence has showed, as LC is also a potent antioxidant: 
in vitro studies, performing mouse myoblasts [18], rat car-
diomyocytes [19] and human osteoblastic cells [20], LC 
supplementation decrease ROS overproduction and cellular 
antioxidant defense system.
Based on LC proprieties, Malaguarnera et al. studied how 
oral LC supplementation improved liver functions and his-
tological patterns in patients with NASH [21]. However, LC 
mechanism of its protective effect on NAFLD remains to be 
elucidated and LC action on hepatic damages induced by 
high fructose intake should be investigated.
The objective of the present study was to clarify the 
underlying mechanisms of LC action in counteracting fruc-
tose-induced hepatic steatosis using human hepatocytes 
(HepG2 cells). In details, we investigated how LC could 
regulate fat deposition and mitochondrial anti-oxidative 
processes.
Materials and methods
Materials
All utilized reagents were purchased from Sigma Chemical 
Co. (St. Louis, MO, U.S.A.).
Primary antibodies against calnexin (H-70),GAPDH (FL-
335), AMPKα1/2 (H-300), pCaMKII (22B1), Nrf2 (C-20), 
PGC1 α (H-300), SOD2 (FL-222), peroxidase-conjugated 
secondary antibodies for western blot analysis and rhoda-
mine/FITC-conjugated antibodies for immunofluorescence 
studies were purchased from Santa Cruz Biotechnology 
(Santa Cruz-CA, U.S.A.). Primary antibody p-AMPKα1/2 
(Thr 172) and CaMKII (6G9) was purchased from Cell Sign-
aling Technology (Danvers-MA, U.S.A.).
Compound C (dorsomorphin), AMPK inhibitor, was 
acquired from Aurogene (Roma, Italy).
Cell line, culture conditions
The human hepatocellular carcinoma cell line HepG2 was 
obtained from the European Collection of Cell Cultures 
(ECACC) and maintained in MEM containing 10% fetal 
bovine serum (FBS), 1% penicillin streptomycin, 1% glu-
tamine, and 1% MEM non-essential amino acid. The cells 
were incubated in a humidified atmosphere of 5%  CO2 at 
37 °C and passaged by trypsinization when they reached 
80% confluence. The culture medium was changed every 
day, following literature indications. For all experiments, 
HepG2 were treated with 5 mM fructose (F) and 5 mM 
l-Carnitine (LC) (single or combined treatment), as indi-
cated in the treatment plan in Fig. 1a. These doses were 
chosen based on literature data [18, 19]. We studied HepG2 
growth capacity to evaluate the absence of cytotoxic effects. 
Growth curve and cell viability test were performed as previ-
ously described. Briefly, HepG2 cells (2 × 105) were plated 
at 40% confluence and grown in MEM. The cells were 
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treated or not with F and LC for 1, 2 or 3 days. Every day 
cells were trypsinized, stained with trypan blue, and counted 
using hemocytometer. Cell viability was calculated by divid-
ing the no stained viable cell count by the total cell count 
[22]. To abolish AMPK activity, we added AMPK inhibitor, 
compound C, at 10 μM for 72 h [23].
Western blot analysis
HepG2 cells were grown in 100 mm culture dishes with 
or without LC combined or not with F. Cellular extracts 
were obtained lysing the cells in RIPA buffer as previ-
ously described [24]. Thirty micrograms of proteins were 
separated by SDS–polyacrylamide gel electrophoreses 
(SDS-PAGE) and electrophoretically transferred to nitro-
cellulose membranes  (Potran®,  Whatman® Schleicher & 
Schuell). The blots were then blocked and probed with 
specific primary antibodies, followed by incubation with 
anti-species-specific secondary antibodies.
To confirm equal protein loading per sample, we used 
antibody anti-calnexin or anti-GAPDH. Detection of spe-
cific proteins was performed by enhanced chemiolumi-
nescence reagent (Western Lightning ECL Pro, Perkin 
Elmer). Quantitative measurement of immunoreactive 
band intensities was performed by densitometry analysis 
using the Scion Image software (Scion Corporation, Fred-
erick, MD, USA). Only for AMPK inhibitor experiments 
and CaMKII, immunoreactive bands were visualized by 
Uvitec Alliance LD9 gel imaging system (Uvitec, Cam-
bridge, UK).
Data were then presented as ratio between treated cells 
and control.
Immunofluorescence
HepG2 cells were grown on coverslips with or without 
5 mM LC combined or not with 5 mM F. After 72 h of 
treatment, cells were washed with PBS, fixed in 4% para-
formaldehyde and lastly, rinsed three times in PBS. Then, 
the cells on the coverslips were incubated for 30 min at room 
temperature with 1% bovine serum albumin in PBS with 
0.2% Triton X-100. HepG2 cells on coverslips were then 
immunostained with specific primary and secondary anti-
bodies, rhodamine- or FITC-conjugated, and nuclei were 
revealed with DAPI staining.
The MITO CytoPainter mitochondrial indicator (Pro-
dotti Gianni, Italy) is a hydrophobic compound that easily 
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Fig. 1  Treatment action on proliferative phase of HepG2 cells. a 
Experimental scheme of HepG2 treatments. b Growth curve and via-
bility determination: treatment with LC, F or LCF not altered HepG2 
proliferative potential. Viability graph showed the absence of cell 
mortality in all treatment conditions. For growth curve and viability, 
a two-way ANOVA test followed by Tukey’s multiple comparison test 
was performed
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permeates intact live cells remaining trapped in mitochon-
dria. This staining was performed on HepG2 live cells.
Cell  ROX® oxidative stress reagents (Thermo Fisher 
Scientific, Italy) are f luorogenic probes designed to 
reliably measure reactive oxygen species (ROS) in live 
cells. The cell-permeable reagents are non-fluorescent or 
very weak fluorescent, while in a reduced state and upon 
oxidation exhibit strong fluorogenic signal. Cell  ROX® 
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Orange Reagents are localized in the cytoplasm. ROS pro-
duction by mitochondria was visualized in fluorescence 
microscopy using the MitoSOX™ red reagent (Thermo 
Fisher Scientific, Italy). These staining were performed 
on HepG2 lived cells after 72 h of treatment.
Slides were mounted with Moviol. Cells were observed 
using Nikon Eclipse 50I microscopy and images were cap-
tured using Nis-Elements D 4.00 software (Nikon Instru-
ments Europe BV-Netherlands).
Oil Red O Staining
Oil Red O bases this technique on the staining of intracel-
lular lipid droplets.
After treatments with LC and F, HepG2 cells were 
washed with PBS and fixed using 4% formalin for 30 min. 
Subsequently, the cells were washed twice-using  ddH2O 
and incubated with Oil Red O solution for 15 min at RT. 
To remove background staining, the cells were washed 
three times with a 60% isopropanol solution for 5 min. 
For quantitative analysis of Oil Red O contents levels, 
isopropanol was added to each samples and then shaken at 
room temperature for 5 min. The absorbance was read at 
490 nm with Bio-rad iMark Microplate Reader (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA).
Statistical analysis
All experiments were performed three times. All data are 
presented as mean ± SD.
Shapiro–Wilk test was used to ascertain normality of 
the data distribution.
For variables with Gaussian distribution, one-way anal-
ysis of variance (ANOVA) was used to compare means 
among the groups (followed by Tukey’s post hoc test), 
whereas for variables with non-Gaussian distribution, 
Kruskal–Wallis test was used to compare means among 
the groups (followed by Dunn’s post hoc test). Results 
were considered significant when p ≤ 0.05.
Statistical analysis was performed with specific sta-
tistical packages (Prism v 7.00 GraphPad Software, San 
Diego, CA, USA).
Results
In this study, the model of steatosis was mimicked using 
human hepatocytes HepG2 treated with 5 mM F for 72 h 
(Fig. 1a). We first verified that 5 mM F, 5 mM LC and com-
bination of F and LC did not cause cytotoxic effects. As 
shown in Fig. 1b, these treatments did not modify growth 
curve and HepG2 vitality. We, therefore, investigated F, LC 
and LCF action on lipid accumulation.
HepG2 intracellular lipid deposition
After 72 h, in CNT condition, a minimal lipid deposition 
occurred, as expected [5], and HepG2 cells treated with LC 
displayed a level of lipid superimposable to CNT (Fig. 2a). 
F-treated HepG2 showed a higher vesicular lipid deposition 
compared to CNT, while LC addition blunted lipid accumu-
lation, as revealed by Oil Red quantification (Fig. 2a).
l‑Carnitine effects on AMPK
We hypothesized that lipid droplets increase was linked to 
AMPK activity.
Figure 2b shows that F significantly decreased AMPK 
activity, while LC supplementation counteracted this altera-
tion. Above all, when HepG2 were treated with 10 μM com-
pound C (an AMPK inhibitor), lipid deposition in F and LCF 
condition was superimposable (Fig. 2c). Moreover, in CNT 
and LC, compound C did not modify minimal lipid accumu-
lation observed. At the same time, we observed that AMPK 
activity is abolished in F, LC and LCF conditions (Fig. 2b).
l‑Carnitine effects on CaMKII
AMPK can be activated by intracellular calcium levels, in 
the same manner of calcium/calmodulin-dependent protein 
kinase II (CaMKII) [25] and our group has recently demon-
strated that LC could regulate the intracellular calcium levels 
[26]. As shown in Fig. 3, 72 h of LC treatment stimulates 
CaMKII protein expression and increases CaMKII activa-
tion. In F-treated HepG2 cells, CaMKII activation is not 
Fig. 2  l-Carnitine role on intracellular lipids deposition. a Oil Red O 
coloration at 72 h of treatment showed how LC does not change intra-
cellular fat deposition in respect to CNT. F treated HepG2 showed a 
higher vesicular lipid deposition compared to CNT, while LC addi-
tion diminished lipid accumulation. The stained lipid content was 
quantified by measuring absorbance at 490 nm. Objective 10X–20X. 
b Western blot analysis reported LC positive action on AMPK protein 
activation at 72 h of treatment: LC counteracted F action that signifi-
cantly decreased AMPK activity. LC action was abolished by 10 μM 
Compound C (an AMPK inhibitor). Immunofluorescence assay 
showed the increase of AMPK protein expression in HepG2 cells 
treated with LC alone or in combined condition LCF with respect 
to CNT and F at 72 h of treatment. Objective: 20X. c Lipid deposi-
tion in F and LCF condition, after treatment with 10 μM Compound 
C (an AMPK inhibitor), was superimposable (Fig. 2c). Moreover, in 
CNT and LC, Compound C did not modify minimal lipid accumula-
tion observed. The stained lipid content was quantified by measuring 
absorbance at 490  nm. ANOVA-Tukey post test: **p ≤ 0.01. Rep-
resentative immunoblots, obtained using Uvitec Alliance LD9 gel 
imaging system, are shown
◂
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modified compared to CNT and the same effect is observed 
in LCF condition.
l‑Carnitine effects on mitochondrial biogenesis 
and anti‑oxidative response
Our group has recently demonstrated that LC could regulate 
cellular anti-oxidative responses [18–20, 26]. Since mito-
chondria are the primary intracellular regulator of ROS bal-
ance, LC effect on mitochondrial activity in HepG2 cells 
was studied. Figure 4a revealed that after 72 h of treatment, 
LC seems to be able to increase fluorescence signal linked to 
mitochondria in respect to CNT, while F seems decreases it. 
Peroxisome proliferator-activated receptor gamma coactiva-
tor 1 (PGC1 α) is a key regulator of mitochondrial dynamics 
and biogenesis [27]. Figure 4b shows how 72 h of LC treat-
ment significantly increased PGC1 protein levels in respect 
to CNT and F: LC counteracted PGC1 α expression inhibi-
tion by F in LCF condition. Moreover, when HepG2 were 
treated with Compound C for 72 h, PGC1 α protein increase 
is completely inhibited in all conditions (Fig. 4c), showing 
an AMPK-dependent LC and F activity on PGC1.
These results suggested that LC, both alone and in the 
presence of fructose, could improve mitochondria ROS 
production. To verify this speculation, we evaluated, with 
a specific fluorescence probe (MitoSOX™), mitochondrial 
ROS production. As reported in Fig. 4d, in F-treated HepG2 
fluorescence intensity is increased in respect to CNT and 
LC, while in LCF condition, ROS signal is attenuated. In 
HepG2 treated with LC, ROS label is similar to CNT.
Additionally, we investigated whether LC antioxidant 
effect is limited to mitochondria or involved other cellular 
compartments. Using ROX Cell  ROX® Oxidative Stress 
Reagents, we observed that after 30 min of  H2O2 stress, ROS 
production was reduced following 72 h of pre-treatment with 
LC, as shown in Fig. 5a. In details, LC seems to be able to 
decrease ROS response both alone (LC) and in the presence 
of fructose (LCF).
Finally, LC supplementation significantly increased 
SOD2 protein levels after 48 h and 72 h of treatment, as 
reported in western blot assay (Fig. 5b). Furthermore, in F 
condition, SOD2 protein levels were significant decreased, 
while LC counterbalanced F effects in HepG2 cells treated 
with combined stimuli (LCF).
Moreover, in Fig. 5b, western blot assay showed how LC 
treatment significantly increased Nrf2 protein content in 
respect to CNT and F stimulation.
Furthermore, Fig. 5c shows that 72 h compound C treat-
ment significantly decreased LC positive action on SOD2 
and Nrf2, indicating an AMPK-dependent modulation by 
LC. In details, SOD2 showed a minimal residual expres-
sion in all three conditions (LC, F, LC + F), suggesting both 
an AMPK-dependent and independent modulation. While, 
NRF2 protein increase was significantly inhibited by AMPK 
inhibitor in LC-treated HepG2, but it maintained a resid-
ual expression in F presence, suggesting that F could also 
enhance NRF2 content in an AMPK-independent manner.
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Fig. 3  l-Carnitine role on CaMKII protein content. Immunofluores-
cence and western blot assay at 72  h of treatment showed how LC 
promoted CaMKII protein expression in HepG2 in respect to CNT 
and in respect to F in combined condition (LCF). Objective: 20X. 
Representative immunoblots, obtained using Uvitec Alliance LD9 gel 
imaging system, are shown
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Discussion
Excessive consumption of fructose, especially sugar-sweet-
ened beverages, is strictly associated with the development 
of liver steatosis [4, 5]. NAFLD is emerging as a primary 
health problem in the world also considering its association 
with diabetes and cardiovascular disease [1, 3].
Now, specifically therapies for NAFLD are limited 
[10–12] and currently lifestyle changes, i.e. diet modifica-
tions and physical activity enlargement, are effective in the 
treatment of liver steatosis [9]. However, several patients are 
not agreeable with healthy these indications. Consequently, 
finding drugs or natural compound that are more useful for 
NAFLD therapy has become one of the hottest research 
fields [13].
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Fig. 4  l-Carnitine role on mithocondria. a MITO CytoPainter stain-
ing revealed that, at 72 h of treatment, LC seems to be able to rise 
the signal of activated mitochondria in respect to CNT and in respect 
to combined condition (LCF). Objective 20X. b Western blot quan-
tification reported PGC1 α increase after LC treatment. This action 
resulted significant after 72  h of treatment. It is important to note 
how this effect resulted also corroborated in the combined condition 
(LCF), in which LC can counteract F action. c Western blot analy-
sis of PGC1 α after 72 h of treatments performed in association with 
AMPK inhibitor: LC positive action on PGC1 α protein content was 
abolish indicated that LC action is AMPK-mediated. d Mito SOX 
staining shown that, at 72  h of treatment, LC does not increase the 
level of mitochondrial ROS compared to CNT. In combination with 
F, LC appears to be able to reduce the levels of mitochondrial ROS 
compared to F. ANOVA-Tukey post test: *p ≤ 0.05, **p ≤ 0.01. Rep-
resentative immunoblots are shown
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Fig. 5  l-Carnitine role on ROS production and antioxidant factors. 
a Cell ROX assay after 30 min of H2O2 stress stimulus showed LC 
protective action in respect to CNT: LC treatment decreased reactive 
oxygen species production in HepG2 cells after 72  h of treatment. 
This action was confirmed also in the combined condition (LCF). 
Objective: 20X. b Western blot analysis of SOD2 and Nrf2 protein 
content after 48 and 72  h of treatment. LC significant promoted 
SOD2 protein levels in HepG2 in respect to control and in respect 
to F in the combined condition (LCF). In the similar manner, LC 
increased Nrf2 protein content after 48 h and 72 h of treatment alone 
and in combined condition (LCF). c Western blot analysis of SOD2 
and Nrf2 protein content after 72 h of treatments LC, F and LC + F 
in association with AMPK inhibitor Compound C: SOD2 showed a 
minimal residual expression in all three conditions suggesting that its 
expression is regulated in AMPK-dependent and independent manner. 
Nrf2 protein content is significantly decreased in LC treated cells, 
while a residual expression was present in F condition suggesting that 
F could also promotes Nrf2 content in an AMPK-independent man-
ner. ANOVA-Tukey post test: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
Representative immunoblots are shown
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We investigated in fructose-induced steatosis HepG2 
cells, the effects of 5 mM LC to clarify LC action in coun-
tering NAFLD.
Our data demonstrate that LC supplementation can 
reduce HepG2 intracellular fructose-induced lipid accumu-
lation, recovering AMPK activity suppressed by fructose 
treatment (Fig. 2a). Use of an AMPK inhibitor (compound 
C) abolishes LC effect, confirming AMPK-mediated LC 
action (Fig. 2c). Recently, Woods et al. have revealed, using 
transgenic mice with AMPK tissue conditional expression, 
that liver-specific activation of this kinase reduces lipo-
genesis in vivo and entirely protects against liver steatosis 
induced by high-fructose diet [5]. Moreover, several studies 
have shown how different nutraceuticals, i.e. pterostilbene 
or paeoniflorin, could reduce lipid accumulation in rats/mice 
fed high fructose diet by activating AMPK signaling and 
thus, promoting β-oxidation and inhibiting lipogenesis [28, 
29].
Furthermore, based on the closed correlation between 
excessive fructose intake, insulin resistance, and NAFLD, 
several studies indicated that metformin, an AMPK activa-
tor, might have therapeutic potential on liver steatosis [30]. 
Moreover, data obtained by increasing number of works 
suggest how SGLT2 inhibitors are an attractive option for 
NAFLD pharmacologic management [31]. Interestingly, 
Mancini et al. have demonstrated that canagliflozin, a SGL2 
inhibitor used in patients with type 2 diabetes, activates 
AMPK in different cell lines and in mouse liver [32, 33]. 
Therefore, LC, used in associated with anti-diabetes drugs, 
could represent a beneficial therapeutic option for NAFLD.
Additionally, AMPK is a  Ca2+-related protein: its activa-
tion may be due to calcium oscillations [34]. We speculated 
that LC could play an important role on calcium signaling 
and, to verify our hypothesis, we analyzed CaMKII pro-
tein level detecting that LC promoted CaMKII expression 
and activation (Fig. 3). These results reveal that LC may 
participate in the regulation of calcium signaling pathways 
confirming our previous data that revealed how LC influ-
ences calcium release from intracellular calcium stores in 
human osteoblasts [26]. Accumulating evidence of the role 
of this nutraceutical on calcium homeostasis opens up new 
therapeutic developments in the pathologies characterized 
by a calcium impairment, including diabetes mellitus and 
cardiovascular diseases.
Numerous data suggest that chronic exposure to a high-
fructose microenvironment could lead to a decrease in 
the mitochondrial biogenesis and a concomitant increase 
in mitochondrial oxidative stress production [35] in 
hepatocytes.
Our data indicated that LC treatment could counteract 
fructose action on mitochondrial biogenesis enhancing 
PGC1 α protein content in steatosis HepG2 (Fig. 4b). As 
known, PGC1 α, the master regulator of mitochondrial 
biogenesis, is primary regulated by AMPK [36]. Therefore, 
LC could maintain mitochondrial homeostasis through 
AMPK activation and subsequently, PGC1 α synthesis as 
indicated by results obtained using AMPK inhibitor (com-
pound C) (Fig. 4b, c). This action could attenuate environ-
mental stress caused by fructose.
As before mentioned, oxidative stress is critically 
involved in NAFLD pathogenesis, because caused lipid 
peroxidation increasing ROS production. In particular, 
high fructose micro-environmental stimulates ROS forma-
tion [4, 6, 7, 35] and this study confirmed the exacerbated 
ROS production not only in mitochondria, but also in other 
cytoplasm compartments (Fig. 4c). Our data reveled as LC 
had an antioxidant effect on steatosis HepG2 cells: ROS 
production was alleviated in mitochondria and in cyto-
plasm. Moreover, the protein content of SOD2 and Nrf2, 
the main factors involved in cellular antioxidant responses, 
were increased in LCF condition in respect to F (Fig. 5b).
SOD2, an important antioxidant enzyme present in 
hepatocytes, thwarts oxidative damages. In fact, it was 
shown that SOD knockout mice presented abnormal lipid 
metabolism in the liver. High levels of oxidative stress, 
caused by defects in the antioxidant system as result of 
concomitant deficiency of SOD in SOD-knockout mice, 
resulted in hepatic lipid accumulation via altered lipid 
metabolism [37].
Our data, obtained by western blot analysis (Fig. 5b, 
c) showed an incremental LC effect on SOD2, which is 
inhibited by compound C, although the permanence of a 
very weak signal suggests a LC residual activity through 
an independent AMPK mechanism. LC increased SOD2 
protein concentration compared to both CNT and F, but 
its effect is not enough to counteract F presence, support-
ing the hypothesis that other AMPK-independent pathways 
are at stake. This evidences agrees with the dichotomous 
SOD2 regulation described in carcinogenic cells, like 
HepG2 cell line [38] and support our date showing that F 
seems to act on SOD2 through both AMPK-dependent and 
-independent manner.
Various studied have shown that fructose downregu-
lated Nrf2 expression and that some natural products ame-
liorate liver steatosis by reverting this effect [14, 37, 39]. 
In agreement with these observations, in our experiment, 
fructose decreased Nrf2 content while LC treatment recov-
ered Nrf2 protein level (Fig. 5b). More importantly, many 
works have revealed the crucial role of Nrf2 in progres-
sion of NAFLD to steatohepatitis: in mice, Nrf2 depletion 
increased ROS production and consequently, liver fibrosis 
and inflammation, the principal pathological features of 
NASH [37].
It is also important to highlight that numerous data have 
indicated how Nrf2 expression is regulated by AMPK acti-
vation [40] and showed by our results obtained using AMPK 
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inhibitor (Fig. 5c). Consequently, our results suggested that 
LC-promoting AMPK activity enhances a synergic action on 
mitochondrial homeostasis and oxidative defense machine 
that could counteract fructose-induced hepatic steatosis.
Interestingly, the results of this work point out on LC anti-
oxidant properties. In line with an increasing number of evi-
dence, our results showed LC ability to reduce ROS produc-
tion and contemporarily to rise the expression of antioxidant 
enzymes, i.e. SOD, catalase and phospholipid hydroperoxide 
glutathione peroxidase in an in vitro, in vivo models and 
humans [41–44]. In this regard, our group established this 
LC ability in skeletal muscle cells model, cardiomyocytes 
and osteoblastic cells observing that this anti-oxidant action 
is strictly correlated with calcium signaling [18–20, 26, 41]. 
Additional investigations are needed to better clarify LC 
antioxidant function and mechanisms.
Conclusion
This experimental study on human hepatocytes was 
designed to verify the protective role of LC against fruc-
tose-induced liver steatosis and to investigate LC molecu-
lar mechanisms of action. In this regard, we studied lipid 
deposition, mitochondrial homeostasis and antioxidant sta-
tus, thus determining AMPK activity and CaMKII, SOD2 
and Nrf2 level.
Taken together, our findings indicated that LC succeeds, 
through AMPK activation, in attenuating fructose-induced 
lipid deposition and, by regulating SOD and Nrf2 activity, 
preserves mitochondrial homeostasis and strengths cellular 
antioxidant machine in human HepG2 cells.
This evidence highlights the potential protective effect of 
this nutraceutical compound in NAFLD.
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